Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer

  • Chris W. D. Armstrong
  • Oksana Lyubomska
  • Melissa J. LaBonte
  • David J. J. WaughEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1786)


Cancer studies have entered an era that is heavily focused on the contribution of the tumor microenvironment. For this reason, in vivo experimentation in an immunodeficient model system is no longer fit for purpose. As a consequence, numerous genetically engineered mouse models (GEMMs) which self-develop tumors have been developed to allow experiments to be performed in a fully immunocompetent setting. One of the most commonly used technologies is Cre-loxP recombination due to its unique ability to control target gene expression in a specified tissue type. However, the major limitation of these models remains the inability to generate sufficient numbers of age-matched mice for a synchronized experimental start date. For this reason, the derivation of cell lines from genetically modified murine prostate tissue is desirable and allows for the generation of syngeneic models via subcutaneous or orthotopic injection.

Key words

Prostate cancer GEMMs Cell line derivation Cre-loxP recombination Mouse prostate dissection Genotyping Syngeneic 



The authors would like to acknowledge the CCRCB laboratory personnel who have helped to optimize these protocols; in particular, we would like to acknowledge Dr. Adam Pickard, Dr. Sharon Eddie Parkinson, and Dr. Lara Dura Perez for their work on cell line derivation from the mouse prostate tissue.


  1. 1.
    Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefGoogle Scholar
  2. 2.
    Park SI, Kim SJ, McCauley LK, Gallick GE (2010) Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Enna SJ (editor-in-chief) et al. Curr Protoc Pharmacol; Chapter 14: Unit 14.15Google Scholar
  3. 3.
    Kos CH (2004) Cre/loxP system for generating tissue-specific knockout mouse models. Nutr Rev 62:243–246PubMedGoogle Scholar
  4. 4.
    Parkitna JR, Engblom D, Schutz G (2009) Generation of Cre recombinase-expressing transgenic mice using bacterial artificial chromosomes. Methods Mol Biol (Clifton, NJ) 530:325–342CrossRefGoogle Scholar
  5. 5.
    Nagy A (2000) Cre recombinase: the universal reagent for genome tailoring. Genesis (New York, NY: 2000) 26:99–109CrossRefGoogle Scholar
  6. 6.
    Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101:61–69CrossRefPubMedGoogle Scholar
  7. 7.
    Michel G, Yu Y, Chang T, Yee JK (2010) Site-specific gene insertion mediated by a Cre-loxP-carrying lentiviral vector. Mol Ther 18:1814–1821CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Suwa T, Nyska A, Haseman JK, Mahler JF, Maronpot RR (2002) Spontaneous lesions in control B6C3F1 mice and recommended sectioning of male accessory sex organs. Toxicol Pathol 30:228–234CrossRefPubMedGoogle Scholar
  9. 9.
    Shappell SB, Thomas GV, Roberts RL et al (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270–2305CrossRefPubMedGoogle Scholar
  10. 10.
    Lukacs RU, Goldstein AS, Lawson DA, Cheng D, Witte ON (2010) Isolation, cultivation and characterization of adult murine prostate stem cells. Nat Protoc 5:702–713CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Chris W. D. Armstrong
    • 1
  • Oksana Lyubomska
    • 1
  • Melissa J. LaBonte
    • 1
  • David J. J. Waugh
    • 1
    Email author
  1. 1.Centre for Cancer Research and Cell Biology (CCRCB)Queen’s University BelfastBelfastUK

Personalised recommendations